Several new cephalosporins have been introduced recently or will be introduced soon. The use of β -lactamase inhibitors continues to be common and a new β -lactamase inhibitor, tazobactam, combined with piperacillin, is expected to be released soon. In this paper we will discuss the current status of the β -lactamase inhibitors and the indications for these agents. Newer oral cephalosporins, cefprozil, loracarbef, cefixime, ceftibuten, and cefpodoxime, will be reviewed and their potential advantages over older agents discussed. The potential clinical significance of the new intravenous cephalosporins, cefipime, and cefpirome, will also be reviewed.